S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   386.92 (+0.16%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.32%)
NIO   7.43 (+1.50%)
BABA   72.38 (-0.89%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.23 (-1.07%)
DIS   90.79 (-1.33%)
AMC   7.02 (-6.28%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   386.92 (+0.16%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.32%)
NIO   7.43 (+1.50%)
BABA   72.38 (-0.89%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.23 (-1.07%)
DIS   90.79 (-1.33%)
AMC   7.02 (-6.28%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   386.92 (+0.16%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.32%)
NIO   7.43 (+1.50%)
BABA   72.38 (-0.89%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.23 (-1.07%)
DIS   90.79 (-1.33%)
AMC   7.02 (-6.28%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   386.92 (+0.16%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.32%)
NIO   7.43 (+1.50%)
BABA   72.38 (-0.89%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.23 (-1.07%)
DIS   90.79 (-1.33%)
AMC   7.02 (-6.28%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)

NeuroBo Pharmaceuticals Stock Price, News & Analysis (NASDAQ:NRBO)

$0.49
+0.00 (+0.41%)
(As of 03:57 PM ET)
Compare
Today's Range
$0.48
▼
$0.52
50-Day Range
$0.41
▼
$0.49
52-Week Range
$0.36
▼
$2.33
Volume
93,777 shs
Average Volume
440,554 shs
Market Capitalization
$19.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media

NRBO stock logo

About NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

NRBO Stock Price History

NRBO Stock News Headlines

December 1, 2023 | finance.yahoo.com
NeuroBo to Participate in Investor Conferences in December
November 14, 2023 | finanznachrichten.de
NeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
December 5, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
November 13, 2023 | msn.com
NeuroBo Pharmaceuticals GAAP EPS of -$0.09 beats by $0.02
November 13, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 6, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
October 17, 2023 | finance.yahoo.com
NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference
September 15, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
December 5, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
August 16, 2023 | finanznachrichten.de
NeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 | markets.businessinsider.com
NeuroBo Appoints Hyung Heon Kim As CEO
August 14, 2023 | finance.yahoo.com
NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT
August 9, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 3, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
August 2, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01
June 27, 2023 | msn.com
NeuroBo Pharma Says Its Weight Loss Candidate Outperforms Major Competitors in Preclinical Obesity Study
June 27, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models
June 24, 2023 | fool.com
NeuroBo Pharmaceuticals (NASDAQ: NRBO)
June 13, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific Sessions
June 13, 2023 | forbes.com
Teva Pharmaceutical Inds
June 6, 2023 | finance.yahoo.com
Here's Why NeuroBo Pharmaceuticals, Inc. (NRBO) Could be Great Choice for a Bottom Fisher
May 12, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors
May 2, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH
April 3, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH
March 31, 2023 | finanznachrichten.de
NeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results
March 30, 2023 | finance.yahoo.com
NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results
January 18, 2023 | marketwatch.com
NeuroBo Pharmaceuticals President, CEO Gil Price Resigns >NRBO
See More Headlines
Receive NRBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NRBO
CUSIP
N/A
CIK
1638287
Web
www.neurobopharma.com
Phone
(857) 702-9600
Fax
734-293-0444
Employees
2
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,970,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-53.17%
Return on Assets
-39.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.54
Quick Ratio
5.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.86 per share
Price / Book
0.58

Miscellaneous

Outstanding Shares
38,810,000
Free Float
38,506,000
Market Cap
$19.20 million
Optionable
Not Optionable
Beta
-0.11
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Hyung-Heon Kim (Age 48)
    CEO, President, Principal Executive & Director
    Comp: $54.22k
  • Mr. Marshall H. Woodworth (Age 65)
    Acting CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Mi-Kyung Kim
    Chief Scientific Officer
  • Mr. Robert Homolka
    Senior Vice President of Clinical Operations

Key Competitors

View All Competitors














NRBO Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroBo Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroBo Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRBO shares.
View NRBO analyst ratings or view top-rated stocks.

How have NRBO shares performed in 2023?

NeuroBo Pharmaceuticals' stock was trading at $0.7175 at the beginning of the year. Since then, NRBO shares have decreased by 30.3% and is now trading at $0.50.
View the best growth stocks for 2023 here.

When is NeuroBo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our NRBO earnings forecast.

How were NeuroBo Pharmaceuticals' earnings last quarter?

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings data on Monday, November, 15th. The company reported ($4.80) earnings per share for the quarter, topping the consensus estimate of ($5.40) by $0.60.

When did NeuroBo Pharmaceuticals' stock split?

NeuroBo Pharmaceuticals's stock reverse split on the morning of Tuesday, September 13th 2022. The 1-30 reverse split was announced on Tuesday, September 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of NeuroBo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX).

Who are NeuroBo Pharmaceuticals' major shareholders?

NeuroBo Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of NeuroBo Pharmaceuticals?

Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NRBO) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -